Trastuzumab-related thrombocytopenia: always a self-limiting complication?
Drudi
F
F
Department of Oncology and Oncohematology, Infermi Hospital, Rimini; Cancer Institute of Romagna, Meldola, Italy. Electronic address: f.drudi1@virgilio.it.
Gianni
L
L
Department of Oncology and Oncohematology, Infermi Hospital, Rimini; Cancer Institute of Romagna, Meldola, Italy.
Fantini
M
M
Department of Oncology and Oncohematology, Infermi Hospital, Rimini; Cancer Institute of Romagna, Meldola, Italy.
Ravaioli
A
A
Department of Oncology and Oncohematology, Infermi Hospital, Rimini; Cancer Institute of Romagna, Meldola, Italy.
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D011379:Prognosis; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000628:therapy; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab